est to evaluate the association of non-alcoholic fatty liver disease with WBC count, given its emerging role as a possible factor influencing the development and progression of atherosclerosis [3] . Unfortunately, data on this condition, which refer to a wide spectrum of liver damage, ranging from simple steatosis to steatohepatitis, advanced fibrosis, and cirrhosis, have not been systematically collected in our study, and therefore no conclusion on the complex relation between liver disease, systemic inflammation, and outcome in NSTE-ACS can be drawn from our study. Another controversial point highlighted in the letter by Balta et al. [1] is the relation between WBC count and C-reactive protein (CRP) as determinants of the prognosis in patients with acute coronary syndrome. However, recent data from the Acute Catheterization and Urgent Intervention Triage Strategy (ACUITY) trial [4] including 13,678 patients with NSTE-ACS showed that the WBC count was an independent predictor of mortality even after adjustment for CRP. Finally, although our study along with other epidemiologic studies consistently demonstrated that an increased baseline WBC count could predict future cardiovascular events, it was not designed to determine whether this relation is causal. Balta et al. [1] commented that WBC values could be indirectly associated with cardiovascular mortality as it is a marker of inflammation associated with atherosclerosis We thank Balta et al. [1] for their interest in our article [2] . Regarding the concerns expressed in their letter, we acknowledge that our paper has some limitations including the fact that we did not address the relation between white blood cell (WBC) count and several conditions such as non-alcoholic fatty liver disease, systemic inflammatory disease, infections, medication for weight loss, and drug addiction, which may have theoretically contributed to determining the link between WBC count and cardiovascular mortality. However, in our study the WBC count was an independent predictor of long-term cardiovascular mortality, even after adjustment for several competing factors exploring the most important and recognized pathways related to outcome in non-ST-segment elevation acute coronary syndrome (NSTEACS). They comprise factors associated with (1) myocardial damage (ECG abnormalities, CK-MB values, left ventricle ejection fraction, and history of previous myocardial infarction); (2) hemodynamic status (blood pressure, heart rate, and Killip class); (3) extent of coronary artery disease (age, creatinine value, ST-segment depression, ST-segment elevation in aVR, previous stroke, and diabetes mellitus), and (4) platelet reactivity (mean platelet volume). Moreover most of the suggested comorbidities are quite rare even in an unselected population of NSTE-ACS as the one included in our study. On the other hand, we acknowledge that it would have been of great interReceived: March 26, 2013 Accepted: March 26, 2013 Published online: May 24, 2013
[1]
Ş. Balta,et al.
Inflammatory Markers May Predict Long-Term Cardiovascular Mortality in Patients with Acute Coronary Syndrome
,
2013,
The Cardiology.
[2]
G. Stone,et al.
Association among leukocyte count, mortality, and bleeding in patients with non-ST-segment elevation acute coronary syndromes (from the Acute Catheterization and Urgent Intervention Triage StrategY [ACUITY] trial).
,
2013,
The American journal of cardiology.
[3]
A. Branzi,et al.
Baseline White Blood Cell Count Is an Independent Predictor of Long-Term Cardiovascular Mortality in Patients with Non-ST-Segment Elevation Acute Coronary Syndrome, but It Does Not Improve the Risk Classification of the GRACE Score
,
2013,
Cardiology.
[4]
A. Franchitto,et al.
Nonalcoholic fatty liver disease and atherosclerosis
,
2012,
Internal and Emergency Medicine.
[5]
Xiang Cheng,et al.
Relationship between plasma inflammatory markers and plaque fibrous cap thickness determined by intravascular optical coherence tomography
,
2009,
Heart.
[6]
Brett E Bouma,et al.
Relationship Between a Systemic Inflammatory Marker, Plaque Inflammation, and Plaque Characteristics Determined by Intravascular Optical Coherence Tomography
,
2007,
Arteriosclerosis, thrombosis, and vascular biology.
[7]
U. Ikeda.
Inflammation and coronary artery disease.
,
2003,
Current vascular pharmacology.
[8]
Alexander Rw.
Inflammation and Coronary Artery Disease
,
1994
.